0001209191-23-045095.txt : 20230808
0001209191-23-045095.hdr.sgml : 20230808
20230808200006
ACCESSION NUMBER: 0001209191-23-045095
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230804
FILED AS OF DATE: 20230808
DATE AS OF CHANGE: 20230808
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Wigzell Hans Lennart Rudolf
CENTRAL INDEX KEY: 0001492766
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-14895
FILM NUMBER: 231153039
MAIL ADDRESS:
STREET 1: OSKAR BAECKSTROMSV.11
CITY: HAGERSTEN
STATE: V7
ZIP: 12935
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Sarepta Therapeutics, Inc.
CENTRAL INDEX KEY: 0000873303
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 930797222
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 215 FIRST STREET
STREET 2: SUITE 415
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-274-4000
MAIL ADDRESS:
STREET 1: 215 FIRST STREET
STREET 2: SUITE 415
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER COMPANY:
FORMER CONFORMED NAME: Sarepta Therapuetics, Inc.
DATE OF NAME CHANGE: 20120712
FORMER COMPANY:
FORMER CONFORMED NAME: AVI BIOPHARMA INC
DATE OF NAME CHANGE: 19980930
FORMER COMPANY:
FORMER CONFORMED NAME: ANTIVIRALS INC
DATE OF NAME CHANGE: 19970123
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2023-08-04
0
0000873303
Sarepta Therapeutics, Inc.
SRPT
0001492766
Wigzell Hans Lennart Rudolf
215 FIRST STREET, SUITE 415
CAMBRIDGE
MA
02142
1
0
0
0
0
Common Stock
2023-08-04
4
M
0
15000
29.03
A
35994
D
Common Stock
2023-08-04
4
S
0
15000
106.72
D
20994
D
Stock Option (right to buy)
29.03
2023-08-04
4
M
0
15000
0.00
D
2015-02-28
2024-02-28
Common Stock
15000
0
D
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $106.42 to $107.04 per share. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price
within the ranges set forth above.
/s/ Ryan Brown, as Attorney-in-Fact for Hans Wigzell
2023-08-08